Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (1): 8-13.DOI: 10.3969/j.issn.1673-8640.2023.01.002
Previous Articles Next Articles
ZHANG Yifan1, LI Changping2, ZHANG Lili1, CHEN Zhong1()
Received:
2022-03-05
Revised:
2022-07-14
Online:
2023-01-30
Published:
2023-03-15
CLC Number:
ZHANG Yifan, LI Changping, ZHANG Lili, CHEN Zhong. Relationship between plasma galectin 3 and low-density lipoprotein cholesterol stratified by ages in patients with cardiovascular disease[J]. Laboratory Medicine, 2023, 38(1): 8-13.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.01.002
组别 | 例数 | 性别 | 吸烟史/例 | 基础疾病史 | WBC计数/ (×109/L) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 高血压/例 | 心力衰竭/例 | 糖尿病/例 | 心肌梗死/例 | ||||||||||||
34~54岁组 | 58 | 39 | 19 | 24 | 33 | 8 | 6 | 12 | 6.47(5.01,7.71) | ||||||||
55~64岁组 | 64 | 44 | 20 | 34 | 41 | 14* | 15 | 16 | 6.65(5.35,8.40) | ||||||||
65~74岁组 | 67 | 40 | 27 | 25 | 44 | 14*# | 14 | 6 | 5.70(5.14,8.07) | ||||||||
75~94岁组 | 68 | 36 | 32 | 20 | 51 | 27*#△ | 16 | 12 | 6.31(5.27,7.58) | ||||||||
统计值 | 4.425 | 4.425 | 8.012 | 4.684 | 12.255 | 4.528 | 6.153 | 2.700 | |||||||||
P值 | 0.219 | 0.219 | 0.046 | 0.196 | 0.007 | 0.210 | 0.104 | 0.440 | |||||||||
组别 | 用药情况 | Hb/ (g/L) | Gal3/ (ng/mL) | ||||||||||||||
ACEI或ARB/ 例 | β受体阻滞剂/ 例 | CCB/例 | 抗凝药物/例 | 降脂药物/例 | |||||||||||||
34~54岁组 | 30 | 29 | 17 | 35 | 30 | 140(129,151) | 0.69(0.49,1.54) | ||||||||||
55~64岁组 | 28 | 27 | 15 | 46 | 42 | 144(133,152)* | 0.73(0.49,2.26) | ||||||||||
65~74岁组 | 26 | 22 | 27 | 50 | 37 | 133(118,145)*# | 0.71(0.44,1.10) | ||||||||||
75~94岁组 | 42 | 38 | 26 | 44 | 44 | 130(113,134)*#△ | 0.77(0.56,1.90) | ||||||||||
统计值 | 8.680 | 8.043 | 5.454 | 3.700 | 3.726 | 35.207 | 3.207 | ||||||||||
P值 | 0.034 | 0.045 | 0.141 | 0.296 | 0.293 | <0.001 | 0.361 | ||||||||||
组别 | NT-proBNP/(ng/mL) | HbA1c/% | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/(mmol/L) | HDL-C/ (mmol/L) | |||||||||||
34~54岁组 | 58(17,128) | 5.60(5.20,6.10) | 4.62±1.15 | 1.45(0.97,2.51) | 3.20±0.86 | 0.99(0.90,1.29) | |||||||||||
55~64岁组 | 58(26,381)* | 6.10(5.53,7.00) | 4.46±1.06* | 1.59(1.07,2.29)* | 2.98±0.79* | 1.04(0.92,1.26) | |||||||||||
65~74岁组 | 139(63,767)*# | 5.90(5.30,6.70) | 4.13±1.18*# | 1.13(0.77,1.66)*# | 2.62±0.88*# | 1.06(0.92,1.42) | |||||||||||
75~94岁组 | 1 588(350,2 750)*#△ | 6.20(5.85,7.08) | 4.08±1.08*#△ | 1.07(0.86,1.45)*#△ | 2.74±0.84*#△ | 1.10(0.92,1.22) | |||||||||||
统计值 | 73.380 | 1.028 | 4.300 | 20.789 | 4.039 | 2.166 | |||||||||||
P值 | <0.001 | 0.795 | 0.017 | <0.001 | 0.001 | 0.539 |
组别 | 例数 | 性别 | 吸烟史/例 | 基础疾病史 | WBC计数/ (×109/L) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 高血压/例 | 心力衰竭/例 | 糖尿病/例 | 心肌梗死/例 | ||||||||||||
34~54岁组 | 58 | 39 | 19 | 24 | 33 | 8 | 6 | 12 | 6.47(5.01,7.71) | ||||||||
55~64岁组 | 64 | 44 | 20 | 34 | 41 | 14* | 15 | 16 | 6.65(5.35,8.40) | ||||||||
65~74岁组 | 67 | 40 | 27 | 25 | 44 | 14*# | 14 | 6 | 5.70(5.14,8.07) | ||||||||
75~94岁组 | 68 | 36 | 32 | 20 | 51 | 27*#△ | 16 | 12 | 6.31(5.27,7.58) | ||||||||
统计值 | 4.425 | 4.425 | 8.012 | 4.684 | 12.255 | 4.528 | 6.153 | 2.700 | |||||||||
P值 | 0.219 | 0.219 | 0.046 | 0.196 | 0.007 | 0.210 | 0.104 | 0.440 | |||||||||
组别 | 用药情况 | Hb/ (g/L) | Gal3/ (ng/mL) | ||||||||||||||
ACEI或ARB/ 例 | β受体阻滞剂/ 例 | CCB/例 | 抗凝药物/例 | 降脂药物/例 | |||||||||||||
34~54岁组 | 30 | 29 | 17 | 35 | 30 | 140(129,151) | 0.69(0.49,1.54) | ||||||||||
55~64岁组 | 28 | 27 | 15 | 46 | 42 | 144(133,152)* | 0.73(0.49,2.26) | ||||||||||
65~74岁组 | 26 | 22 | 27 | 50 | 37 | 133(118,145)*# | 0.71(0.44,1.10) | ||||||||||
75~94岁组 | 42 | 38 | 26 | 44 | 44 | 130(113,134)*#△ | 0.77(0.56,1.90) | ||||||||||
统计值 | 8.680 | 8.043 | 5.454 | 3.700 | 3.726 | 35.207 | 3.207 | ||||||||||
P值 | 0.034 | 0.045 | 0.141 | 0.296 | 0.293 | <0.001 | 0.361 | ||||||||||
组别 | NT-proBNP/(ng/mL) | HbA1c/% | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/(mmol/L) | HDL-C/ (mmol/L) | |||||||||||
34~54岁组 | 58(17,128) | 5.60(5.20,6.10) | 4.62±1.15 | 1.45(0.97,2.51) | 3.20±0.86 | 0.99(0.90,1.29) | |||||||||||
55~64岁组 | 58(26,381)* | 6.10(5.53,7.00) | 4.46±1.06* | 1.59(1.07,2.29)* | 2.98±0.79* | 1.04(0.92,1.26) | |||||||||||
65~74岁组 | 139(63,767)*# | 5.90(5.30,6.70) | 4.13±1.18*# | 1.13(0.77,1.66)*# | 2.62±0.88*# | 1.06(0.92,1.42) | |||||||||||
75~94岁组 | 1 588(350,2 750)*#△ | 6.20(5.85,7.08) | 4.08±1.08*#△ | 1.07(0.86,1.45)*#△ | 2.74±0.84*#△ | 1.10(0.92,1.22) | |||||||||||
统计值 | 73.380 | 1.028 | 4.300 | 20.789 | 4.039 | 2.166 | |||||||||||
P值 | <0.001 | 0.795 | 0.017 | <0.001 | 0.001 | 0.539 |
组别 | LDL-C | HDL-C | TG | TC |
---|---|---|---|---|
34~54岁组 | ||||
r值 | 0.219 | 0.107 | -0.157 | 0.153 |
P值 | 0.099 | 0.426 | 0.239 | 0.251 |
55~64岁组 | ||||
r值 | 0.357 | 0.156 | 0.119 | 0.328 |
P值 | <0.001 | 0.222 | 0.352 | 0.009 |
65~74岁组 | ||||
r值 | 0.525 | 0.199 | 0.248 | 0.439 |
P值 | <0.001 | 0.116 | 0.048 | <0.001 |
75~94岁组 | ||||
r值 | -0.021 | 0.053 | -0.075 | 0.009 |
P值 | 0.864 | 0.671 | 0.546 | 0.864 |
组别 | LDL-C | HDL-C | TG | TC |
---|---|---|---|---|
34~54岁组 | ||||
r值 | 0.219 | 0.107 | -0.157 | 0.153 |
P值 | 0.099 | 0.426 | 0.239 | 0.251 |
55~64岁组 | ||||
r值 | 0.357 | 0.156 | 0.119 | 0.328 |
P值 | <0.001 | 0.222 | 0.352 | 0.009 |
65~74岁组 | ||||
r值 | 0.525 | 0.199 | 0.248 | 0.439 |
P值 | <0.001 | 0.116 | 0.048 | <0.001 |
75~94岁组 | ||||
r值 | -0.021 | 0.053 | -0.075 | 0.009 |
P值 | 0.864 | 0.671 | 0.546 | 0.864 |
项目 | 例数 | Gal3/ (ng/mL) | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/ (mmol/L) | HDL-C/ (mmol/L) |
---|---|---|---|---|---|---|
服用降脂药物 | 153 | 0.77(0.60,1.85) | 4.29±1.18 | 1.24(0.88,1.94) | 2.88±0.91 | 1.07(0.90,1.29) |
未服用降脂药物 | 104 | 0.62(0.43,1.11) | 4.35±1.06 | 1.24(0.93,1.79) | 2.87±0.79 | 1.05(0.91,1.24) |
统计值 | -3.692 | -0.426 | -0.257 | -0.088 | -0.023 | |
P值 | <0.001 | 0.670 | 0.797 | 0.869 | 0.982 |
项目 | 例数 | Gal3/ (ng/mL) | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/ (mmol/L) | HDL-C/ (mmol/L) |
---|---|---|---|---|---|---|
服用降脂药物 | 153 | 0.77(0.60,1.85) | 4.29±1.18 | 1.24(0.88,1.94) | 2.88±0.91 | 1.07(0.90,1.29) |
未服用降脂药物 | 104 | 0.62(0.43,1.11) | 4.35±1.06 | 1.24(0.93,1.79) | 2.87±0.79 | 1.05(0.91,1.24) |
统计值 | -3.692 | -0.426 | -0.257 | -0.088 | -0.023 | |
P值 | <0.001 | 0.670 | 0.797 | 0.869 | 0.982 |
项目 | β值 | 标准误 | Wald值 | OR值(95%CI) | P值 |
---|---|---|---|---|---|
Gal3 | 0.358 | 0.265 | 1.825 | 1.431(0.851~2.408) | 0.177 |
吸烟史 | -0.050 | 0.592 | 0.007 | 0.951(0.298~3.039) | 0.933 |
降脂药物 | 0.000 | 0.628 | 0.000 | 1.000(0.292~3.421) | 1.000 |
高血压史 | 1.293 | 0.615 | 4.420 | 3.643(1.091~12.168) | 0.036 |
项目 | β值 | 标准误 | Wald值 | OR值(95%CI) | P值 |
---|---|---|---|---|---|
Gal3 | 0.358 | 0.265 | 1.825 | 1.431(0.851~2.408) | 0.177 |
吸烟史 | -0.050 | 0.592 | 0.007 | 0.951(0.298~3.039) | 0.933 |
降脂药物 | 0.000 | 0.628 | 0.000 | 1.000(0.292~3.421) | 1.000 |
高血压史 | 1.293 | 0.615 | 4.420 | 3.643(1.091~12.168) | 0.036 |
项目 | β值 | 标准误 | Wald值 | OR值(95%CI) | P值 |
---|---|---|---|---|---|
Gal3 | 0.667 | 0.261 | 6.531 | 1.948(1.169~3.247) | 0.011 |
吸烟史 | -0.753 | 0.528 | 2.034 | 0.471(0.167~1.325) | 0.154 |
降脂药物 | 1.283 | 0.530 | 5.860 | 3.609(1.278~10.193) | 0.015 |
高血压史 | 1.463 | 0.589 | 6.170 | 4.320(1.361~13.711) | 0.013 |
糖尿病史 | 1.089 | 0.625 | 3.036 | 2.970(0.871~10.123) | 0.082 |
项目 | β值 | 标准误 | Wald值 | OR值(95%CI) | P值 |
---|---|---|---|---|---|
Gal3 | 0.667 | 0.261 | 6.531 | 1.948(1.169~3.247) | 0.011 |
吸烟史 | -0.753 | 0.528 | 2.034 | 0.471(0.167~1.325) | 0.154 |
降脂药物 | 1.283 | 0.530 | 5.860 | 3.609(1.278~10.193) | 0.015 |
高血压史 | 1.463 | 0.589 | 6.170 | 4.320(1.361~13.711) | 0.013 |
糖尿病史 | 1.089 | 0.625 | 3.036 | 2.970(0.871~10.123) | 0.082 |
组别 | 例数 | 年龄/岁 | 性别 | 吸烟史/例 | 糖尿病史/例 | 高血压史/例 | Gal3/ (ng/mL) | LDL-C/ (mmol/L) | |
---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | ||||||||
对照组 | 189 | 62.96±13.26 | 122 | 67 | 79 | 34 | 127 | 0.69(0.47,1.27) | 3.09(2.51,3.60) |
心力衰竭组 | 63 | 69.76±14.37 | 33 | 30 | 23 | 15 | 38 | 0.90(0.58,2.76) | 2.51(2.09,3.30) |
统计值 | 3.452 | 2.956 | 2.956 | 0.549 | 1.144 | 0.989 | -3.132 | -2.908 | |
P值 | 0.001 | 0.086 | 0.086 | 0.459 | 0.285 | 0.320 | 0.002 | 0.004 |
组别 | 例数 | 年龄/岁 | 性别 | 吸烟史/例 | 糖尿病史/例 | 高血压史/例 | Gal3/ (ng/mL) | LDL-C/ (mmol/L) | |
---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | ||||||||
对照组 | 189 | 62.96±13.26 | 122 | 67 | 79 | 34 | 127 | 0.69(0.47,1.27) | 3.09(2.51,3.60) |
心力衰竭组 | 63 | 69.76±14.37 | 33 | 30 | 23 | 15 | 38 | 0.90(0.58,2.76) | 2.51(2.09,3.30) |
统计值 | 3.452 | 2.956 | 2.956 | 0.549 | 1.144 | 0.989 | -3.132 | -2.908 | |
P值 | 0.001 | 0.086 | 0.086 | 0.459 | 0.285 | 0.320 | 0.002 | 0.004 |
[1] | LI X, TANG X, LU J, et al. Therapeutic inhibition of galectin3 improves cardiomyocyte apoptosis and survival during heart failure[J]. Mol Med Rep, 2018, 17(3):4106-4112. |
[2] | GAO Z, LIU Z, WANG R, et al. Galectin-3 is a potential mediator for atherosclerosis[J]. J Immunol Res, 2020, 2020:5284728. |
[3] | WHAYNE T F. Low-density lipoprotein cholesterol (LDL-C):how low?[J]. Curr Vasc Pharmacol, 2017, 15(4):374-379. |
[4] |
PEI C, ZHANG Y, WANG P, et al. Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways[J]. Phytother Res, 2019, 33(2):294-308.
DOI PMID |
[5] |
CHEN X, LIN J, HU T, et al. Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrin β1-RhoA-JNK signaling activation[J]. J Cell Physiol, 2019, 234(7):10990-11000.
DOI PMID |
[6] |
OU H C, CHOU W C, HUNG C H, et al. Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway[J]. Environ Toxicol, 2019, 34(7):825-835.
DOI URL |
[7] |
ZHANG P, SU Q, YE X, et al. Trends in LDL-C and non-HDL-C levels with age[J]. Aging Dis, 2020, 11(5):1046-1057.
DOI |
[8] | 诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华健康管理学杂志, 2017, 11(1):7-28. |
[9] | 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789. |
[10] |
NILSSON-EHLE H, JAGENBURG R, LANDAHL S, et al. Blood haemoglobin declines in the elderly:implications for reference intervals from age 70 to 88[J]. Eur J Haematol, 2000, 65(5):297-305.
DOI URL |
[11] |
MARIES L, MANITIU I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)[J]. Cardiovasc J Afr, 2013, 24(7):286-289.
DOI PMID |
[12] | GSECKA A, ROGULA S, SZARPAK, et al. LDL-cholesterol and platelets:insights into their interactions in atherosclerosis[J]. Life (Basel), 2021, 11(1):39. |
[13] | LIU F T, HSU D K, ZUBERI R I, et al. Expression and function of galectin-3,a beta-galactoside-binding lectin,in human monocytes and macrophages[J]. Am J Pathol, 1995, 147(4):1016-1028. |
[14] | ESFAHANI N S, WU Q, KUMAR N, et al. Aging influences the cardiac macrophage phenotype and function during steady state and during inflammation[J]. Aging Cell, 2021, 20(8):e13438. |
[15] |
TABAS I, LICHTMAN A H. Monocyte-macrophages and T cells in atherosclerosis[J]. Immunity, 2017, 47(4):621-634.
DOI PMID |
[16] | BEHRADMANESH S, NASRI P. Serum cholesterol and LDL-C in association with level of diastolic blood pressure in type 2 diabetic patients[J]. J Renal Inj Prev, 2012, 1(1):23-26. |
[17] |
ATHYROS V G, DOUMAS M, IMPRIALOS K P, et al. Diabetes and lipid metabolism[J]. Hormones (Athens), 2018, 17(1):61-67.
DOI PMID |
[18] |
CASTIGLIONE V, AIMO A, VERGARO G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2):625-643.
DOI |
[19] |
BI J, GARG V, YATES A R. Galectin-3 and sST2 as prognosticators for heart failure requiring extracorporeal life support:Jack n' Jill[J]. Biomolecules, 2021, 11(2):166.
DOI URL |
[20] | 唐颖茜. 不同射血分数心衰患者临床及实验室相关指标分析[D]. 昆明: 昆明医科大学, 2017. |
[1] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[2] | MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664. |
[3] | YANG Qiong, XU Fen, LIN Yahui. Clinical application of cardiac troponin determination in pediatric cardiac involvement related diseases [J]. Laboratory Medicine, 2023, 38(6): 510-517. |
[4] | YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523. |
[5] | SU Zhenzhen, ZOU Jihua, WANG Huimin, XU Weifeng, DING Fang, ZHANG Jingmei, WANG Zhanke. Consistency of serum LDL-P and LDL-C determination results [J]. Laboratory Medicine, 2023, 38(2): 148-152. |
[6] | XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945. |
[7] | SHEN Ying, XU Xiaoping, ZHANG Lele, DU Yongping, MENG Chao. Clinical value of LDL-C determination in non-fasting blood samples [J]. Laboratory Medicine, 2022, 37(11): 1049-1056. |
[8] | PENG Yanjun, HAN Xuejing, TANG Hongxia, CHEN Junmeng, JIA Kegang. Correlation between nuclear magnetic resonance spectroscopy and traditional biochemical determination methods analyzer for determining blood lipid [J]. Laboratory Medicine, 2021, 36(7): 733-737. |
[9] | LI Jing, QUAN Hui, ZENG Zhirong, WEI Yi. Establishment of the reference interval of small and dense low-density lipoprotein cholesterol in apparently healthy adults in Chengdu [J]. Laboratory Medicine, 2021, 36(6): 609-614. |
[10] | WANG Qian, ZHU Shiyao, LU Di, ZHU Kun, WU Jiong, QUAN Jiali. Arteriosclerotic cardiovascular disease risk markers research progress [J]. Laboratory Medicine, 2021, 36(4): 447-452. |
[11] | ZHAO Jingjing, ZHANG Peng, ZHOU Yong, CAO Yingping, HUANG Zhihu, FU Shengmiao, WANG Yuming, HONG Guolin, SHEN Jun, ZHENG Lei. A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China [J]. Laboratory Medicine, 2021, 36(12): 1222-1228. |
[12] | ZHU Yonglin, WANG Lüya, YAN Shengkai. Research progress in the methodology and clinical application of low-density lipoprotein receptor gene mutation and function determination [J]. Laboratory Medicine, 2021, 36(12): 1287-1291. |
[13] | SONG Yunxiao, GE Wen, ZHANG Haichen, YUAN Wenhua, DAI Jun, YOU Wenshi. Role of remnant lipoprotein cholesterol in the management of blood lipid [J]. Laboratory Medicine, 2019, 34(5): 394-400. |
[14] | WANG Shengkui, ZHOU Jun. Role of small and dense low-density lipoprotein cholesterol in cardiovascular and cerebrovascular diseases [J]. Laboratory Medicine, 2019, 34(1): 19-22. |
[15] | LIANG Chunzi, ZHU Man, TU Jiancheng. Research progress of VAP in determining plasma lipoprotein subfractions [J]. Laboratory Medicine, 2019, 34(1): 76-81. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||